Bin Zhao

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also affiliated with Fujian Medical University, Xiamen University, First Affiliated Hospital of Xiamen University, Zhongshan Hospital of Xiamen University, Second Affiliated Hospital of Fujian Medical University

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer”.

Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer

Clinical Lung Cancer(2022)10.1016/j.cllc.2022.04.005

N/A

0.489DataRank · unranked

14 citations

W. Victoria Lai, Raffaele Califano, Salma K. Jabbour, Charles M. Rudin, Corinne Faivre‐Finn +8 more

Healthy lifestyle partly mediates the association between self-rated health and risk of overall and cause-specific mortality

BMC Medicine(2025)10.1186/s12916-025-04399-y

N/A

0DataRank · unranked

4 citations

Bin Zhao, Yi Yang, Kai Yu, Linda M. Liao, Stephanie J. Weinstein +5 more